Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses
Key facts
- Who runs it
- Shandong University
- Where
- China6 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 406 people enrolled
- Started
- 1 Jul 2022
- Ended
- 1 Feb 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Amoxicillin
- Tetracycline tid
- Tetracycline qid
- Bismuth Potassium Citrate
- Colloidal Bismuth Pectin
- Esomeprazole 20mg
- Record updated
- 27 March 2024
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patients aged 18-70
- Patients with H.pylori infection (Positive for rapid urease test or 13C/14C-urea breath test)
- Patients who have never received H. pylori eradication treatment
Who cannot take part
- Patients with serious underlying diseases, such as liver insufficiency (Aspartate aminotransferase or alanine aminotransferase greater than 1.5 times the normal value), renal insufficiency (Cr≥2.0mg/dL or glomerular filtration rate <50 ml/min), immunosuppression, malignant tumors, Coronary heart disease or coronary artery stenosis ≥75%
- Patients with active gastrointestinal bleeding
- Patients with a history of upper gastrointestinal surgery
- Patients allergic to treatment drugs
- Patients with medication history of bismuth agents, antibiotics, proton pump inhibitor and other drugs within 4 weeks
- Patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse
- Patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial
- Patients who are unwilling or incapable to provide informed consents
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a dose and frequency of tetracycline 500mg tid or qid of bismuth quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
The 2 groups in the trial
- Tid groupTreatment being tested
Tid group: Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 20mg bid
Treatment: Amoxicillin, Tetracycline tid, Bismuth Potassium Citrate, Colloidal Bismuth Pectin, and Esomeprazole 20mg
- Qid groupExisting treatment, for comparison
Qid group: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 20mg bid
Treatment: Amoxicillin, Tetracycline qid, Bismuth Potassium Citrate, Colloidal Bismuth Pectin, and Esomeprazole 20mg
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Multicenter Randomized Clinical Trial of Different Tetracycline Doses and Frequencies.
- Publications
- Record updated
- 27 March 2024